SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 27, 2003; DOI 10.1182/blood-2003-01-0014. This Article Full Text (PDF) All Versions of this Article: 2003-01-0014v1 102/3/810    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nieva, J. Articles by Saven, A. Search for Related Content PubMed PubMed Citation Articles by Nieva, J. Articles by Saven, A. Social Bookmarking                   What's this? Submitted January 3, 2003 Accepted March 20, 2003 Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia Jorge Nieva, Kelly Bethel, and Alan Saven* Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA Department of Pathology, Scripps Clinic, La Jolla, CA, USA * Corresponding author; email: saven.alan{at}scrippshealth.org. Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts.) ultimately relapse. Twenty-four HCL pts.(21 male, 3 female), with a median age of 53.5 years, having relapsed after prior treatment with cladribine, were treated with rituximab at 375mg/m2 intravenously weekly x 4. Three pts. (13%) achieved complete remissions and 3 pts. (13%) partial responses. Thus, six of 24 (25%) pts. achieved a response following rituximab. At a median follow-up of 14.6 months, 2 responders have relapsed; median time to relapse not yet reached. The only grade III or IV toxicities demonstrated were culture-negative febrile neutropenia, transient and reversible disseminated intravascular coagulation related to rituximab administration, and a diverticular abscess, each in single patients. Of 18 non-responders, 9 pts. subsequently received other treatments; 5 pts. were retreated with cladribine, 3 underwent splenectomy and 1 received pentostatin. Follow up data are available on 7 of these 9 patients; all 7 patients achieved improvements in hematologic parameters. Rituximab, administered at this dose and schedule, has only modest single agent activity in cladribine-failed HCL patients when compared to other agents active in this disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Forconi, E. Sozzi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, L. Rigacci, F. Gherlinzoni, R. Cantaffa, A. Baraldi, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior Blood, November 19, 2009; 114(21): 4696 - 4702. [Abstract] [Full Text] [PDF] R. J. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia J. Clin. Oncol., June 20, 2009; 27(18): 2983 - 2990. [Abstract] [Full Text] [PDF] R. Zenhausern, M. Simcock, A. Gratwohl, U. Hess, M. Bargetzi, A. Tobler, and on behalf of the Swiss Group for Clinical Cancer R Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98) Haematologica, September 1, 2008; 93(9): 1426 - 1428. [Full Text] [PDF] H. M. Golomb Hairy Cell Leukemia: Treatment Successes in the Past 25 Years J. Clin. Oncol., June 1, 2008; 26(16): 2607 - 2609. [Full Text] [PDF] F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al. Eradication of minimal residual disease in hairy cell leukemia Blood, June 15, 2006; 107(12): 4658 - 4662. [Abstract] [Full Text] [PDF] E. Arons, I. Margulies, L. Sorbara, M. Raffeld, M. Stetler-Stevenson, I. Pastan, and R. J. Kreitman Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin. Cancer Res., May 1, 2006; 12(9): 2804 - 2811. [Abstract] [Full Text] [PDF] F. Ravandi and S. O'Brien Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., December 1, 2005; 80(12): 1660 - 1674. [Abstract] [PDF] R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies J. Clin. Oncol., September 20, 2005; 23(27): 6719 - 6729. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020